Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells
- 450 Downloads
Glioblastoma Multiforme (GBM) is a malignant primary brain tumor associated with poor survival rate. PI3K/Akt pathway is highly upregulated in gliomas due to deletion or mutation of PTEN and its activation is associated with tumor grade. mTOR is downstream from PI3K/Akt pathway and it initiates translation through its action on S6K and 4E-BP1. mTOR is an important therapeutic target in many cancers, including glioblastomas. Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment. In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells. Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 μM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone. These results suggest the importance of combining chemopreventive with chemotherapeutic agents in order to increase the efficacy of chemotherapeutic drugs.
KeywordsGlioblastoma Rapamycin Isoflavones mTOR
Our work was supported, in part, by grants from Faculty Research Committee grant # 937, and University Research Committee grant # FY2002-09 at Idaho State University, and NIH/NCRR INBRE grant # P20RR16454. We thank Eric Neilson for his technical help.
- 1.Central Brain Tumor Registry of the Unites States. Statistical report: primary brain tumors in the Unites States, 2000–2004. CBTRUS; 2007-2008Google Scholar
- 2.Kufe DW, Pollock RE, Weichselbaum RR et al (2004) Cancer Medicine 6. BC Decker, New York, pp 1195–1231Google Scholar
- 3.Jeffrey Bruce: Glioblastoma Multiforme. eMedicine February, (2005)Google Scholar
- 12.Cheng JQ, Nicosia SV (2001) AKT signal transduction pathway in oncogenesis. Encylopedia reference of cancer. Springer, Berlin, pp 35–37Google Scholar
- 20.Huang S, Houghton PJ (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opinion Invest Drugs 3:295–304Google Scholar
- 34.Goudar RK, Shi Q, Hjelmeland MD et al (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101–112PubMedGoogle Scholar
- 48.Sehdev V, Lai JC, Bhushan A (2009) Biochanin A modulates cell viability, invasion and growth promoting signaling pathways in HER-2-positive breast cancer cells. J Oncol (In Press)Google Scholar
- 60.Dowling RJ, Pollak M, Sonenberg N (2009) Current status and challenges associated with targeting mTOR for cancer therapy. Bio Drugs 23(2):77–91Google Scholar